Edition:
United Kingdom

Taro Pharmaceutical Industries Ltd (TARO.N)

TARO.N on New York Stock Exchange

98.63USD
24 Sep 2018
Change (% chg)

$-0.79 (-0.79%)
Prev Close
$99.42
Open
$99.32
Day's High
$99.32
Day's Low
$98.63
Volume
7,060
Avg. Vol
11,732
52-wk High
$128.25
52-wk Low
$93.59

Latest Key Developments (Source: Significant Developments)

Taro Pharmaceutical Industries Reports Q4 EPS $2.17
Thursday, 17 May 2018 

May 17 (Reuters) - Taro Pharmaceutical Industries Ltd ::TARO PROVIDES RESULTS FOR YEAR ENDED MARCH 31, 2018.Q4 EARNINGS PER SHARE $2.17.Q4 SALES $175.2 MILLION.FY EARNINGS PER SHARE $6.18 EXCLUDING ITEMS.  Full Article

Taro Pharmaceutical quarterly earnings per share $1.30
Wednesday, 8 Nov 2017 

Nov 7 (Reuters) - Taro Pharmaceutical Industries Ltd :Quarterly earnings per share $1.30.Quarterly sales $169.9 million.Taro Pharmaceutical Industries Ltd-qtrly ‍shr $1.30​.  Full Article

Taro announces joining of CEO
Friday, 1 Sep 2017 

Sept 2 (Reuters) - Taro Pharmaceutical Industries Ltd :Taro announces joining of CEO.Taro Pharmaceutical Industries Ltd - ‍ Uday Baldota has joined company as its chief executive officer ("CEO") effective August 28, 2017​.Says Uday bBaldota appointed CEO.Taro Pharmaceutical Industries Ltd - Baldota replaces mr. Abhay Gandhi, who served in role of interim chief executive officer since January 1, 2017.Taro Pharmaceutical Industries Ltd - Gandhi will continue in his role as vice chairman of Taro board and as CEO of Sun Pharma North America operations​.  Full Article

Taro reports quarterly net income per ordinary share $1.35
Wednesday, 9 Aug 2017 

Aug 9 (Reuters) - Taro Pharmaceutical Industries Ltd -:Taro provides results for quarter ended June 2017.Quarterly sales $161.3 million.Qtrly net income per ordinary share $1.35.  Full Article

Bellus Health to sell subsidiary Thallion Pharmaceuticals to Taro Pharmaceuticals
Thursday, 16 Mar 2017 

Bellus Health Inc : Press release - Bellus Health announces the sale of subsidiary Thallion Pharmaceuticals to Taro Pharmaceuticals . Bellus Health Inc - deal for total consideration of CA$2.7 million . Bellus Health Inc- in addition will receive a portion of certain post-approval revenues related to shigamab program .Bellus Health Inc - "upfront proceeds from this transaction also meaningfully extend our cash runway to Q4 2018".  Full Article

Taro posts quarterly sales of $220.4 million
Thursday, 9 Feb 2017 

Taro Pharmaceutical Industries Ltd : Taro provides results for December 31, 2016 . Quarterly sales $220.4 million .Taro Pharmaceutical Industries Ltd qtrly net income per ordinary share from continuing operations attributable to taro $3.42.  Full Article

UPDATE 3-Canada seeks U.S. help to solve EpiPen shortage

TORONTO, April 17 Canada said on Tuesday it is working with the U.S. Food and Drug Administration to access supplies of Mylan N.V.'s EpiPen emergency allergy antidote amid a growing shortage that has spared the United States.